A new trading day began on Monday, with Plus Therapeutics Inc (NASDAQ: PSTV) stock price up 3.36% from the previous day of trading, before settling in for the closing price of $0.37. PSTV’s price has ranged from $0.16 to $2.31 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 46.51%. Meanwhile, its annual earnings per share averaged 66.32%. With a float of $60.31 million, this company’s outstanding shares have now reached $60.49 million.
Considering the fact that the conglomerate employs 21 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is -116.81%, operating margin of -1167.47%, and the pretax margin is -2120.25%.
Plus Therapeutics Inc (PSTV) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Plus Therapeutics Inc is 0.29%, while institutional ownership is 2.64%. The most recent insider transaction that took place on May 15 ’25, was worth 20,276. Before that another transaction happened on Sep 13 ’24, when Company’s Director bought 4,000 for $1.50, making the entire transaction worth $5,996. This insider now owns 15,188 shares in total.
Plus Therapeutics Inc (PSTV) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.13 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 66.32% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 49.58% during the next five years compared to 46.51% growth over the previous five years of trading.
Plus Therapeutics Inc (NASDAQ: PSTV) Trading Performance Indicators
Here are Plus Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 0.99. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.46.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.50, a number that is poised to hit -0.09 in the next quarter and is forecasted to reach -0.43 in one year’s time.
Technical Analysis of Plus Therapeutics Inc (PSTV)
Compared to the last year’s volume of 19.68 million, its volume of 7.99 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 85.09%.
During the past 100 days, Plus Therapeutics Inc’s (PSTV) raw stochastic average was set at 10.28%, which indicates a significant decrease from 81.43% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.0342 in the past 14 days, which was lower than the 0.1509 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.3541, while its 200-day Moving Average is $0.9312.
